Steven Cohen Aldeyra Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$5.77 - $9.93 $49,102 - $84,504	8,510 New	8,510 $84,000
Q1 2021 May 17, 2021	SELL	$6.53 - $14.42 $5.6 Million - $12.4 Million	-858,270 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$6.31 - $8.13 $1.37 Million - $1.76 Million	216,352 Added 33.7%	858,270 $5.89 Million
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $2.57 Million - $4.83 Million	641,918 New	641,918 $4.76 Million
Q3 2019 Nov 15, 2019	SELL	$4.41 - $6.12 $1.43 Million - $1.99 Million	-325,000 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$6.0 - $9.0 $1.95 Million - $2.93 Million	325,000 New	325,000 $1.95 Million

116

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $298M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.